BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 25859666)

  • 21. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
    Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
    Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.
    Rodriguez-Lebron E; Denovan-Wright EM; Nash K; Lewin AS; Mandel RJ
    Mol Ther; 2005 Oct; 12(4):618-33. PubMed ID: 16019264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.
    Liu KY; Shyu YC; Barbaro BA; Lin YT; Chern Y; Thompson LM; James Shen CK; Marsh JL
    Hum Mol Genet; 2015 Mar; 24(6):1602-16. PubMed ID: 25398943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo.
    Graham RK; Deng Y; Carroll J; Vaid K; Cowan C; Pouladi MA; Metzler M; Bissada N; Wang L; Faull RL; Gray M; Yang XW; Raymond LA; Hayden MR
    J Neurosci; 2010 Nov; 30(45):15019-29. PubMed ID: 21068307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.
    Kovalenko M; Dragileva E; St Claire J; Gillis T; Guide JR; New J; Dong H; Kucherlapati R; Kucherlapati MH; Ehrlich ME; Lee JM; Wheeler VC
    PLoS One; 2012; 7(9):e44273. PubMed ID: 22970194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Exogenous NUB1 Expression in the Striatum of HDQ175/Q7 Mice.
    Vodicka P; Chase K; Iuliano M; Valentine DT; Sapp E; Lu B; Kegel-Gleason KB; Sena-Esteves M; Aronin N; DiFiglia M
    J Huntingtons Dis; 2016 Jun; 5(2):163-74. PubMed ID: 27314618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
    Gabery S; Sajjad MU; Hult S; Soylu R; Kirik D; Petersén Å
    Eur J Neurosci; 2012 Sep; 36(6):2789-800. PubMed ID: 22731249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
    McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
    Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleolar stress controls mutant Huntington toxicity and monitors Huntington's disease progression.
    Sönmez A; Mustafa R; Ryll ST; Tuorto F; Wacheul L; Ponti D; Litke C; Hering T; Kojer K; Koch J; Pitzer C; Kirsch J; Neueder A; Kreiner G; Lafontaine DLJ; Orth M; Liss B; Parlato R
    Cell Death Dis; 2021 Dec; 12(12):1139. PubMed ID: 34880223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.
    Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW
    Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease.
    Zuleta A; Vidal RL; Armentano D; Parsons G; Hetz C
    Biochem Biophys Res Commun; 2012 Apr; 420(3):558-63. PubMed ID: 22445760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.
    Zala D; Benchoua A; Brouillet E; Perrin V; Gaillard MC; Zurn AD; Aebischer P; Déglon N
    Neurobiol Dis; 2005 Dec; 20(3):785-98. PubMed ID: 16006135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential morphology and composition of inclusions in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Wanderer J; Morton AJ
    Histochem Cell Biol; 2007 May; 127(5):473-84. PubMed ID: 17285342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease.
    Estrada-Sánchez AM; Burroughs CL; Cavaliere S; Barton SJ; Chen S; Yang XW; Rebec GV
    J Neurosci; 2015 Mar; 35(10):4440-51. PubMed ID: 25762686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.
    Menalled LB; Sison JD; Dragatsis I; Zeitlin S; Chesselet MF
    J Comp Neurol; 2003 Oct; 465(1):11-26. PubMed ID: 12926013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse.
    Brown TB; Bogush AI; Ehrlich ME
    Hum Mol Genet; 2008 Oct; 17(20):3095-104. PubMed ID: 18632688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The selective vulnerability of nerve cells in Huntington's disease.
    Sieradzan KA; Mann DM
    Neuropathol Appl Neurobiol; 2001 Feb; 27(1):1-21. PubMed ID: 11298997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant Adeno Associated Viral (AAV) vector type 9 delivery of Ex1-Q138-mutant huntingtin in the rat striatum as a short-time model for in vivo studies in drug discovery.
    Ceccarelli I; Fiengo P; Remelli R; Miragliotta V; Rossini L; Biotti I; Cappelli A; Petricca L; La Rosa S; Caricasole A; Pollio G; Scali C
    Neurobiol Dis; 2016 Feb; 86():41-51. PubMed ID: 26626080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
    Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW
    Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.